Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state

Journal of Neural Transmission, Supplementa

Volumn , Issue 72, 2007, Pages 145-148

  Pollak, L ^a   Dobronevsky, Y ^a   Prohorov, T ^a   Bahunker, S ^a   Rabey, J M ^a  

^a NONE

Author keywords

freezing; methylphenidate; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; METHYLPHENIDATE;

AGED; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GAIT; HUMAN; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; TREATMENT OUTCOME; WALKING;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GAIT; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; TREATMENT OUTCOME; WALKING;

EID: 38449119611     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-73574-9_17     Document Type: Article

References (24)

1. Amsten AF (1997) Catecholamine regulation of the prefrontal cortex. J Psychopharmacol (Oxf) 11:151-162
2. Auriel E, Hausdorff JM, Herman T, Simon ES, Giladi N (2006) Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease. Clin Neuropharmacol 29:15-17
3. Balash Y, Peretz Ch, Leibovich G, Herman T, Hausdorff JM, Giladi N (2005) Falls in outpatients with Parkinson's disease. Frequency, impact and identifying factors. J Neurol 252:1310-1315
4. Barbeau A (1976) Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 33:333-338
5. Benamer HT, Patterson J, Wyper DJ et al. (2000) Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15:692-698
6. Bloem BR, Hausdorff JM, Visser JE, Giladi N (2004) Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 19:871-884
7. Camicioli R, Lea E, Nutt JG, Sexton G, Oken BS (2001) Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study. Clin Neuropharmacol 24:208-213
8. Fahn S (1995) The freezing phenomenon in parkinsonism. Adv Neurol 67:53-63
9. Finnegan KT (1993) Neurotoxins and monoamine oxidase inhibition: new aspects. Mov Disord 8 Suppl 1: S14-S19
10. Hashimoto T (2006) Speculation on the responsible sites and pathophysiology of freezing of gait. Parkinsonims Relat Disord 12: S55-S62
11. Honey GD, Suckling J, Zelaya F, Long C, Routledge C, Jackson S, Ng V, Fletcher PC, Williams SCR, Brown J, Bullmore ET (2003) Dopaminergic drug effects on physiological connectivity in a human corticostriato-thalamic system. Brain 126:1767-1781
12. Ichise M, Kim YJ, Ballinger JR et al. (1999) SPECT imaging of preand postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 52:1206-1214
13. Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonine, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037
14. Meador-Woodruff JH, Damask SP, Watson SJ Jr (1994) Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc Natl Acad Sci USA 91:8297-8301
15. Nutt JG, Carter JH, Sexton GJ (2004) The dopamine transporter: importance in Parkinson's disease. Ann Neurol 55:766-773
16. Panisset M (2004) Freezing of gait in Parkinson's disease. Neurol Clin 22: S53-S62
17. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F et al. (2003) A comparative randomized study of rasagiline versus placebo or entacapone as adjunct to levodopa in Parkinson's disease patients with motor fluctuations (the LARGO study). Presented at the 7th Congress of the European Federation of Neurological Societies (EFNS). Helsinki, Finland, August 30-September 2
18. Ribeiro MJ, Vidailhet M, Loc'h C et al. (2002) Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol 59:580-586
19. Seeman P, Madras BK (1998) Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 3:386-396
20. Seibyl JP, Marek KL, Quinlan D et al. (1995) Decreased single-photon emission computed tomographic [123-I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38:589-598
21. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, Le Witt P et al. (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51:604-612
22. Toghi H, Abe T, Takahashi S (1993a) The effects of L-threo-3, 4, dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gate in parkinsonian patients. J Neural Transm 5:27-34
23. Toghi H, Abe T, Takahashi S, Takahashi J, Hamato H (1993b) Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms. Neurosci Lett 150:71-74
24. Toghi H, Abe T, Takahashi S, Takahashi J, Nozaki Y, Ueno M et al. (1993c) Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes. J Neural Transm 5:17-26